Two Sigma Advisers LP Buys 56,400 Shares of Avantor, Inc. (NYSE:AVTR)

Two Sigma Advisers LP raised its stake in Avantor, Inc. (NYSE:AVTR - Free Report) by 63.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 144,900 shares of the company's stock after buying an additional 56,400 shares during the period. Two Sigma Advisers LP's holdings in Avantor were worth $3,053,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Tidal Investments LLC increased its stake in Avantor by 59.6% in the 4th quarter. Tidal Investments LLC now owns 18,869 shares of the company's stock valued at $398,000 after purchasing an additional 7,048 shares in the last quarter. Rhumbline Advisers increased its position in shares of Avantor by 1.8% in the fourth quarter. Rhumbline Advisers now owns 1,922,368 shares of the company's stock valued at $40,504,000 after buying an additional 33,692 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Avantor by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,027,636 shares of the company's stock worth $63,792,000 after buying an additional 74,735 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Avantor by 6.9% during the 4th quarter. Blue Trust Inc. now owns 8,069 shares of the company's stock worth $170,000 after buying an additional 522 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its position in shares of Avantor by 38.1% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 119,063 shares of the company's stock worth $2,509,000 after buying an additional 32,838 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Trading Down 1.0%

Shares of AVTR stock traded down $0.13 during trading hours on Friday, reaching $12.91. 11,443,298 shares of the stock traded hands, compared to its average volume of 7,958,956. The company has a quick ratio of 0.70, a current ratio of 1.07 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $8.80 billion, a PE ratio of 12.41, a PEG ratio of 1.55 and a beta of 1.09. Avantor, Inc. has a 1-year low of $11.82 and a 1-year high of $28.00. The business has a fifty day moving average price of $14.08 and a 200 day moving average price of $17.93.

Avantor (NYSE:AVTR - Get Free Report) last issued its earnings results on Friday, April 25th. The company reported $0.23 EPS for the quarter, meeting analysts' consensus estimates of $0.23. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a return on equity of 12.17% and a net margin of 10.49%. The business's quarterly revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 earnings per share. On average, equities research analysts forecast that Avantor, Inc. will post 1.06 EPS for the current year.

Insiders Place Their Bets

In related news, Director Gregory L. Summe purchased 30,000 shares of the stock in a transaction on Friday, May 23rd. The shares were bought at an average price of $12.50 per share, for a total transaction of $375,000.00. Following the completion of the acquisition, the director now directly owns 100,000 shares in the company, valued at approximately $1,250,000. This trade represents a 42.86% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph R. Massaro acquired 8,100 shares of the company's stock in a transaction dated Tuesday, April 29th. The stock was acquired at an average price of $12.30 per share, for a total transaction of $99,630.00. Following the completion of the purchase, the director now directly owns 35,038 shares of the company's stock, valued at $430,967.40. This trade represents a 30.07% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 83,100 shares of company stock valued at $1,027,630 over the last ninety days. Corporate insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

AVTR has been the subject of several analyst reports. Robert W. Baird cut their price target on Avantor from $21.00 to $17.00 and set an "outperform" rating for the company in a report on Monday, April 28th. Raymond James reaffirmed an "outperform" rating and set a $24.00 price target (down from $26.00) on shares of Avantor in a report on Monday, February 10th. Wells Fargo & Company dropped their price target on shares of Avantor from $25.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Stifel Nicolaus cut shares of Avantor from a "buy" rating to a "hold" rating and decreased their price objective for the company from $26.00 to $14.00 in a research report on Monday, April 28th. Finally, TD Cowen lowered Avantor from a "buy" rating to a "hold" rating and set a $15.50 target price on the stock. in a research report on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $18.88.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.